Medline Inc. enters its June 11 earnings date carrying a striking new development: its private equity backers just sold over $2.3 billion worth of stock, and the short sellers who dominated the prior week's story have actually pulled back.
The ownership change is the dominant signal this week. On May 28, Hellman & Friedman and affiliated holding companies offloaded roughly 63 million shares at $36.54 apiece — a combined disposal worth well over $2.3 billion. Blackstone separately trimmed 22.4 million shares over the same period. These are not open-market sellers reacting to a news event; they are the original private equity sponsors reducing their stakes in size. Hellman & Friedman now holds 70.9 million shares, down from levels consistent with a much larger position, while Blackstone has dropped to 101.8 million. The sales came at prices well above where the stock trades today — MDLN closed at $33.19 on June 2, down 8.2% on the week and 25.8% over the past month. That gap between the PE exit price and the current market tells its own story about how sentiment has deteriorated since the secondary.
Short interest tells a more nuanced story now — and that is a meaningful change from the May 27 note, which flagged 33.4 million shares and a climbing ORTEX short score as the primary risk. Estimated short interest has since pulled back to 29.5 million shares, down from that late-May peak. The ORTEX short score has followed, easing from 62.3 to 55.2 over the same period. That is still elevated relative to where it began May — at roughly 19 million shares — but the aggressive rebuild phase appears to have paused. Borrow conditions remain very accommodating. The cost to borrow is just 0.62%, barely changed on the week despite all the share-price action. Availability is running at 321% of current short interest, loosening further from the 195% reading flagged last week. Shares are plentiful in the lending market. There is no squeeze dynamic here.
Options positioning offers little additional drama. The put/call ratio is 0.46, almost exactly in line with its 20-day average of 0.47, and the z-score is essentially zero. The 52-week PCR range runs from 0.12 to 1.97 — the current reading sits near the call-heavy end of that spectrum. Options traders are not positioning for a crisis. That disconnect between a stock down 26% in a month and options that look unremarkable is itself worth noting.
The Street is broadly bullish but acknowledging the pressure. Baird lowered its target to $45 from $57 on June 3, keeping its Outperform rating intact. Barclays moved to $45 from $50 on June 1, holding Overweight. Both cuts came after the PE secondary and the stock's continued decline. The consensus price target is $51.59, implying roughly 55% upside from current levels — a gap that reflects analyst conviction in the longer-term thesis even as near-term estimates get trimmed. The bull case centres on Medline's Mpower platform, its 340,000-product portfolio, and strong prime vendor relationships. The bear case points to tariff-driven margin pressure and the difficulty of gaining share when competitors face the same headwinds. Valuation has compressed sharply: the P/E has fallen nearly 8 points over the past 30 days to 21x, and the EV/EBITDA has dropped about 0.65 turns to 12.9x — the stock is getting cheaper, but not yet cheap enough to overwhelm near-term execution concerns.
The earnings history for MDLN is unambiguous. The last two prints produced a roughly 7-8% drop on the day and an additional 6-7% over the following five sessions. Given that pattern, the June 11 release is the single most important variable to watch — not whether the shorts rebuild further or whether Hellman & Friedman sells again, but whether Medline can change the narrative on margins and tariff pass-through before another post-print slide compounds the damage from a month that has already taken the stock down more than a quarter.
See the live data behind this article on ORTEX.
Open MDLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
